Provided by Tiger Trade Technology Pte. Ltd.

MapLight Therapeutics, Inc.

8.83
-0.3200-3.50%
Post-market: 8.830.00000.00%19:30 EDT
Volume:495.36K
Turnover:4.40M
Market Cap:490.73M
PE:-1.75
High:9.42
Open:9.15
Low:8.70
Close:9.15
52wk High:40.43
52wk Low:8.70
Shares:55.58M
Float Shares:19.23M
Volume Ratio:1.36
T/O Rate:2.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0580
EPS(LYR):-18.5643
ROE:-111.55%
ROA:-67.11%
PB:1.41
PE(LYR):-0.48

Loading ...

MapLight Therapeutics Initiated at Neutral by Guggenheim

Dow Jones
·
Oct 06

Press Release: MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

Dow Jones
·
Oct 06

Guggenheim Initiates MapLight Therapeutics at Neutral

MT Newswires Live
·
Oct 06

MapLight Therapeutics initiated with a Neutral at Guggenheim

TIPRANKS
·
Oct 06

US and German Scientists Win Nobel Medicine Prize for Work on Light and Brain

Reuters
·
Oct 05

MapLight Therapeutics Currently Down 11 Consecutive Days, on Pace for Record Losing Streak

Dow Jones
·
Sep 30

MapLight Therapeutics on Track for Record Losing Streak

Dow Jones
·
Sep 25

Maplight Therapeutics General Counsel Kristopher Hanson Sells 16,509 Shares for $192,654.03

Reuters
·
Sep 19

MapLight Therapeutics files to sell 13.18M shares of common stock for holders

TIPRANKS
·
Sep 10

Maplight Therapeutics - Prospectus Covers Resale of up to 13,181,055 Common Shares by Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Sep 10

MapLight Therapeutics to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 09

MapLight Therapeutics price target lowered to $43 from $45 at Needham

TIPRANKS
·
Aug 31

Catalyst4 Acquires $50.07 Million of MapLight Therapeutics Common Shares

Reuters
·
Aug 19

Morgan Stanley Keeps Their Hold Rating on MapLight Therapeutics, Inc. (MPLT)

TIPRANKS
·
Aug 17

MapLight Therapeutics price target lowered to $21 from $24 at Canaccord

TIPRANKS
·
Aug 16

Analysts’ Top NA Picks: Solv Energy (MWH), MapLight Therapeutics, Inc. (MPLT)

TIPRANKS
·
Aug 14

MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate

Benzinga Earnings
·
Aug 14

MapLight Q2 FY26 Net Loss Widens to $60.19 Million; R&D Expenses Rise to $53.44 Million

Reuters
·
Aug 14

Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
Aug 14

MapLight Therapeutics Prices USD 150 Million PIPE at USD 11.38 a Share

Reuters
·
Aug 13